Whitehawk Therapeutics, Inc. Common StockWHWK
About: Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
Employees: 53
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
309% more call options, than puts
Call options by funds: $94K | Put options by funds: $23K
100% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 4 (+2) [Q4]
91% more capital invested
Capital invested by funds: $24.7M [Q3] → $47.2M (+$22.5M) [Q4]
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
2% more funds holding
Funds holding: 52 [Q3] → 53 (+1) [Q4]
31% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 16
Research analyst outlook
We haven’t received any recent analyst ratings for WHWK.
Financial journalist opinion
Based on 3 articles about WHWK published over the past 30 days


